Medication cost savings associated with @entity353 for XXXX non-insulin-dependent @entity6 @entity1 and @entity1 .

@entity1 @entity2175 @entity101 @entity28 @entity6 @entity353
BACKGROUND: The cost of @entity6 can be defined in both medical and economic terms. Although there is an abundance of literature concerning the medical management of @entity6 , few studies have assessed the financial impact of its treatment. This study examined the savings in prescription costs associated with a weight reduction program for @entity28 @entity1 and @entity1 with @entity2175 ( @entity2175 ). RESEARCH DESIGN AND METHODS: Forty subjects ages 40-70 years who had body mass indexes of 30-40 kg/m2 and @entity2175 of more than 1 year duration were assigned to one of two 800-kcal weight-loss programs for 12 weeks. A cost analysis was done on the 32 subjects who were taking anti- @entity101 and/or anti- @entity6 medications. A list of medications and monthly amounts was obtained at the start, upon completion, and 1 year following completion of the diet. The average out-of-pocket cost for a month's supply of each prescription was calculated by polling 16 retail pharmacies in Lexington, Kentucky. RESULTS: Subjects lost an average of 15.3 kg (33.7 lb) over the 12 weeks. At 1-year follow-up, subjects maintained a mean 9.0-kg (19.8 lb) @entity353 . The average monthly prediet out-of-pocket cost for anti- @entity101 and anti- @entity6 medications and supplies was  63.30 per subject. Following completion of the diet, this cost per month decreased to  20.40 and at 1-year follow-up the average monthly cost per subject was  32.40. The estimated average savings in prescription costs per subject over the year was  442.80. CONCLUSIONS: Significant short- and long-term savings in prescription costs were obtained following a 12-week hypocaloric weight reduction program for @entity28 individuals with @entity2175 .
